Global Targeted Drugs for Allergic Diseases Market Growth (Status and Outlook) 2024-2030

Global Targeted Drugs for Allergic Diseases Market Growth (Status and Outlook) 2024-2030

Anaphylaxis is an inappropriate reaction of the immune system to normal harmless substances. It generally has a rapid onset, strong reaction, and rapid subsidence. It has obvious genetic tendencies and individual differences. Currently, the prevalence of allergic diseases is increasing rapidly worldwide, affecting approximately 25% of the global population. Abnormalities in type 2 immune pathways are important factors in inducing allergic diseases. Type 2 immune pathway refers to an inflammatory pathway in which Th2 cells (T helper 2) play a key role, and various cytokines such as IL-4, IL-5, IL-13, and TSLP are involved. Depending on where the inflammatory reaction occurs, abnormal type 2 immune pathways can induce different allergic diseases, such as skin (atopic dermatitis, chronic spontaneous urticaria, etc.), respiratory tract (chronic sinusitis, asthma, chronic obstruction, etc.) lung disease, etc.), digestive tract (eosinophilic esophagitis), cardiovascular (eosinophilic granulomatous vasculitis), etc. Biological targeted drugs mainly reduce the inflammatory response and activity of immune cells by binding to targets such as specific regulatory factors in the type 2 immune pathway; Small molecule targeted drugs include JAK inhibitors and TYK2 inhibitors, which exert immunomodulatory effects by blocking the JAK/STAT pathway. Compared with traditional anti-allergic drugs, targeted drugs have better efficacy in severe or drug-resistant patients, and the drugs themselves are safer, and have gradually become the mainstream trend in the development of anti-allergic drugs.

The global Targeted Drugs for Allergic Diseases market size is projected to grow from US$ 36340 million in 2024 to US$ 91900 million in 2030; it is expected to grow at a CAGR of 16.7% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Targeted Drugs for Allergic Diseases Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Allergic Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Allergic Diseases sales for 2023 through 2029. With Targeted Drugs for Allergic Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Allergic Diseases industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Allergic Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Allergic Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Allergic Diseases market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Allergic Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Allergic Diseases.

Global key players of Targeted Drugs for Allergic Diseases include Sanofi, AbbVie, Novartis, Incyte, Roche, etc. The top five players hold a share over 76%. North America is the largest market, and has a share about 68%, followed by Europe with share 18%. In terms of product type, IL-4R is the largest segment, occupied for a share of 37%. In terms of application, Asthma has a share about 35 percent.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Allergic Diseases market by product type, application, key players and key regions and countries.

Segmentation by Type:
IL-4R
TSLP
IL-5
JAK
IgE
IL-13
Others

Segmentation by Application:
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Chronic Obstructive Pulmonary Disease
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
IL-4R
TSLP
IL-5
JAK
IgE
IL-13
Others

Segmentation by Application:
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Chronic Obstructive Pulmonary Disease
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
AbbVie
Novartis
Incyte
Roche
AstraZeneca
GSK
Eli Lilly and Company
Amgen
Pfizer
Leo Pharma
Teva
Otsuka Pharmaceutical
Mabpharm

Please note: The report will take approximately 2 business days to prepare and deliver.